Literature DB >> 30178019

Parkinson Disease.

Houman Homayoun1.   

Abstract

Parkinson disease is a common neurodegenerative disorder that causes progressive motor and nonmotor disability. It is diagnosed clinically and requires a detailed history and neurologic examination to exclude alternative diagnoses. Although disease-modifying therapies do not exist for Parkinson disease, effective symptomatic therapies, including dopaminergic medications and surgery, allow patients to maintain good quality of life for many years. Nonmotor symptoms, including mood, cognitive, sleep, autonomic, and gastrointestinal symptoms, should be managed by a multidisciplinary team of clinicians. Recent advances include new diagnostic criteria from the Movement Disorder Society and the addition of new symptomatic therapies for treating motor complications and nonmotor symptoms in advanced disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30178019     DOI: 10.7326/AITC201809040

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  21 in total

Review 1.  Mitophagy in Human Diseases.

Authors:  Laura Doblado; Claudia Lueck; Claudia Rey; Alejandro K Samhan-Arias; Ignacio Prieto; Alessandra Stacchiotti; Maria Monsalve
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

Review 2.  Mitophagy, a Form of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamics of Parkinson's Disease.

Authors:  Xiao-Le Wang; Si-Tong Feng; Ya-Ting Wang; Yu-He Yuan; Zhi-Peng Li; Nai-Hong Chen; Zhen-Zhen Wang; Yi Zhang
Journal:  Cell Mol Neurobiol       Date:  2021-02-02       Impact factor: 5.046

Review 3.  Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies.

Authors:  Cheng-Fu Su; Li Jiang; Xiao-Wen Zhang; Ashok Iyaswamy; Min Li
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

4.  Clinical study of the effects of deep brain stimulation on urinary dysfunctions in patients with Parkinson's disease.

Authors:  Huantao Zong; Fangang Meng; Yong Zhang; Guangzhu Wei; Huiqing Zhao
Journal:  Clin Interv Aging       Date:  2019-06-25       Impact factor: 4.458

Review 5.  Mitophagy in Parkinson's Disease: From Pathogenesis to Treatment.

Authors:  Jia Liu; Weijin Liu; Ruolin Li; Hui Yang
Journal:  Cells       Date:  2019-07-12       Impact factor: 6.600

6.  The effect of the PARK16 rs11240572 variant on brain structure in Parkinson's disease.

Authors:  Lu-Yan Gu; Shao-Bing Dai; Cheng Zhou; Ting Gao; Jing-Jing Wu; Yi Fang; Xiao-Jun Guan; Tao Guo; Ran Zheng; Chongyao Jin; Xiao-Jun Xu; Zhe Song; Jun Tian; Xinzhen Yin; Min-Min Zhang; Bao-Rong Zhang; Yaping Yan; Jiali Pu
Journal:  Brain Struct Funct       Date:  2021-08-09       Impact factor: 3.270

7.  Opposing functions of β-arrestin 1 and 2 in Parkinson's disease via microglia inflammation and Nprl3.

Authors:  Yinquan Fang; Qingling Jiang; Shanshan Li; Hong Zhu; Rong Xu; Nanshan Song; Xiao Ding; Jiaqi Liu; Miaomiao Chen; Mengmeng Song; Jianhua Ding; Ming Lu; Guangyu Wu; Gang Hu
Journal:  Cell Death Differ       Date:  2021-03-08       Impact factor: 15.828

8.  Nervonic acid amends motor disorder in a mouse model of Parkinson's disease.

Authors:  Dandong Hu; Yujuan Cui; Ji Zhang
Journal:  Transl Neurosci       Date:  2021-05-25       Impact factor: 1.757

9.  Mild Parkinsonian Signs, Energy Decline, and Striatal Volume in Community-Dwelling Older Adults.

Authors:  Qu Tian; Rebecca Ehrenkranz; Andrea L Rosso; Nancy W Glynn; Lana M Chahine; James Hengenius; Xiaonan Zhu; Caterina Rosano
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-04-01       Impact factor: 6.591

10.  Dysfunction in superior frontal gyrus associated with diphasic dyskinesia in Parkinson's disease.

Authors:  Yu-Ting Shen; Yong-Sheng Yuan; Min Wang; Yan Zhi; Jian-Wei Wang; Li-Na Wang; Ke-Wei Ma; Qian-Qian Si; Ke-Zhong Zhang
Journal:  NPJ Parkinsons Dis       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.